CLINICIAN INTERVIEW ACUTE OTITIS MEDIA IN THE ERA OF PCV-7. Interview with Stanley L. Block, Jr, MD, FAAP
|
|
- Bryan Cooper
- 6 years ago
- Views:
Transcription
1 ACUTE OTITIS MEDIA IN THE ERA OF PCV-7 Interview with Stanley L. Block, Jr, MD, FAAP Dr Block is president of Kentucky Pediatric Research and has practiced full-time primary care pediatrics in rural Bardstown, Ky, for the past 22 years. He has been board recertified twice and holds appointments as Clinical Professor of Pediatrics at the University of Louisville and the University of Kentucky. Dr Block received his Doctor of Medicine degree from the University of Kentucky and completed his postgraduate work in pediatrics at Wake Forest University School of Medicine. For significant contributions to pediatric medicine, Dr Block has been awarded the 1998 Researcher of the Year in Pediatric Private Practice by the American Academy of Pediatrics; the 2001 Charles Bluestone Award by the American Society of Pediatric Otolaryngology; the 2002 and 2003 Burtis Burr Breese Award by the Pediatric Infectious Disease Society; and the 2004 Distinguished Alumnus Award by the University of Kentucky Medical School. Kentucky Pediatric Research is one of the largest pediatric ambulatory research groups in the United States, participating in more than 250 clinical trials. Dr Block is a reviewer for several publications, including the Pediatric Infectious Disease Journal, Pediatrics, Southern Medical Journal, the Journal of Pediatrics, and Pediatric Drugs. He serves as a writer and editorial board advisor for the Pediatric Infectious Disease Journal, Infectious Diseases in Children, and Pediatric Annals, as well as the quarterly Pediatric Infections Forum. He is the co-chief editor for and an advisory board member of the National Campaign for Influenza Prevention and an advisory board member of the National Alliance for Advancement of ADHD Care. Dr Block is a recognized opinion leader on infectious diseases in ambulatory pediatrics, having published, as first author or co-author, more than 130 original papers, review articles, and abstracts on acute otitis media (AOM), vaccines, microbiology, antibiotic resistance in pediatrics, and attention-deficit/hyperactivity disorder. He was first author of landmark papers describing the role of penicillin-resistant pneumococcus in AOM, Chlamydia pneumoniae in AOM, and C pneumoniae and Mycoplasma pneumoniae in community-acquired pneumonia in children. He has presented clinical data at annual meetings of the American Academy of Pediatrics, the Society for Pediatric Research, and the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), and at pediatric grand rounds across the United States, Canada, and Europe. In the following interview with Advanced Studies in Medicine (ASiM), Dr Block discusses what impact immunization of the pediatric population with 7-valent pneumococcal conjugate vaccine (PCV-7) will have on AOM. ASiM: How important are the third dose and the booster dose of PCV-7 for full protection against vaccine serotypes? Dr Block: The first 3 doses of PCV-7 have a major impact on invasive disease. For most children, the peak occurrence of AOM is between 6 and 18 to 24 months of age. 1,2 Consequently, optimizing protection against mucosal disease such as AOM after 12 months is very important. Prelicensure evaluation of PCV-7 in infants within Kaiser Permanente found that more than 97% of recipients of PCV-7 Advanced Studies in Medicine S937
2 achieved 0.15 mg/ml or greater anticapsular antibody for all serotypes after the primary series of 3 doses, which correlates with the observed protective efficacy for invasive disease of 97.3%. The children were randomized by a ratio of 1:1 to receive PCV-7 or control vaccine at 2, 4, 6, and 12 to 15 months of age. 3 However, the data for children who received the third dose late or not at all suggest that protection against mucosal disease did not last to 12 months of age without the third dose. 4 Additionally, PCV-7 was most effective shortly after the booster dose (ie, during ages 15 to 18 months) when vaccinated children had 12.2% fewer otitis visits than control children (95% confidence interval, 8.2 to 16.0). 4 Thus, the available immunologic data suggests that the booster dose after 12 months of age is an important facet of protection against mucosal disease, 4 whereas 2 or 3 doses are probably sufficient to protect most children against invasive disease. 5 ASiM: Your participation in multiple clinical trials of PCV-7 has enabled you to immunize 94% of your pediatric patients with PCV-7 since What changes in the rate of upper respiratory tract infections have you seen in your pediatric population now that the majority has received at least 2 to 3 doses of PCV-7? Dr Block: We have seen an impact far exceeding previous expectations of PCV-7 on rates of both AOM and sinusitis, and also on the number of total antibiotic days. We compared annual rates of AOM, sinusitis, and antibiotic use during the first 3 years of life in a cohort of 274 children consecutively born from 1993 through 1994 (pre PCV-7) with a cohort of 221 children consecutively born from 2000 through 2001, 94% of whom received 3 or 4 doses of PCV-7. 6 Both cohorts of children were 91% white, and nearly half were enrolled in day care. The mean number of AOM episodes during the first 3 years of life was reduced by 19% in the PCV-7 cohort compared with the pre PCV-7 cohort. Surprisingly, the biggest impact was actually in year 3, when there was a 29% reduction. 6 With regard to rates of sinusitis, there was an impressive 59% reduction (range 39%-69% annually) in the first 3 years of life in the PCV-7 cohort compared with the pre PCV-7 cohort (Block SL, unpublished data, 2004). ASiM: Has the influence of herd immunity in your study exceeded previous predictions of protection of AOM? Dr Block: Herd immunity is the indirect protection from infection of susceptible members of a population brought about by the presence of immune individuals. Along with the profound shift in AOM microbiology with the advent of PCV-7, we have also seen a much greater impact on overall AOM rates than the modest 6% to 9% drop suggested by premarket studies. Before PCV-7, we did about 100 to 125 ear taps a year for kids with more than 2 treatment failures. Now it is 25 to 35, tops. We are just not seeing severe AOM anymore. I attribute this impact largely to herd immunity, which explains why it was not seen in earlier studies. They were done in small segments of their respective populations, in contrast to our community where almost all children have been vaccinated. So, we have seen notable herd immunity occurring on rates of AOM and sinusitis in the relatively closed population within our area when rates of uptake and availability of PCV-7 are high. Some critics say these findings are the result of the more stringent diagnostic criteria for pediatric AOM and acute bacterial rhinosinusitis (ABRS) that have been developed and propagated by public health officials over the past decade. Yet, these criteria likely had no impact on our results. All of the pediatricians were experienced otoscopists who have performed tympanocentesis for routine care and clinical research, 7 and our clinicians were already using defined parameters confirmed by clinical examination. Our diagnostic accuracy for AOM has been corroborated in multiple clinical trials using tympanometry, acoustic reflectometry, and/or especially tympanocentesis. Indeed, our diagnostic criteria for pediatric AOM and ABRS have remained consistent for the last 12 years. Therefore, the changes in rates of infection that we observed were strictly related to the introduction of PCV-7. But this also means that for practices using poor examination technique, looser diagnostic criteria, looser prescriptive pens, or disposable speculums and otoscopes with alkaline batteries, the reduction on rates of AOM and sinusitis likely will be much less perceptible. ASiM: With regard to the etiology of AOM, have you seen changes in the rates of recovery of the predominant pathogens? Dr Block: I think a historical perspective will help S938 Vol. 4 (10E) December 2004
3 us understand this issue. Approximately cases of invasive Haemophilus influenzae occurred in the United States in the early 1980s. In 1985, the first H influenzae type B (Hib) vaccine was introduced followed by a conjugate Hib vaccine in The widespread use of these vaccines has resulted in a greater than 99% decline in invasive disease compared with the early 1980s. This dramatic decline in invasive H influenzae disease was an impressive public health benefit but it also altered the bacterial etiology of AOM. As H influenzae decreased, Streptococcus pneumoniae became the more prevalent cause of bacterial AOM. Now that a conjugate pneumococcal vaccine has been mandated in children, it is not unexpected that the use of PCV-7 has also had a major impact on the prevalence of the key AOM pathogens. Among children aged 7 to 24 months with severe and/or refractory AOM, we compared 336 AOM isolates obtained from 1992 to 1998 (pre PCV-7) with 83 AOM isolates obtained from 2000 to 2003 from children who had received 3 or 4 doses of PCV-7. 2 The rate of gram-negative pathogens increased from 50% to 66% (P <.001). Nontypeable H influenzae increased from 41% to 56% (P =.01). 2 Among gram-negative AOM isolates, the overall rate of beta-lactamase producing organisms increased from 32% to 47% (P =.007) 2 showing that beta-lactamase producing gram-negative organisms are responsible for about half of all middle ear isolates. Among PCV-7 vaccinated children who had recurrent AOM (defined as an episode of AOM within 7 to 28 days of the last dose of antibiotic), we found that 72% of cases were due to H influenzae rather than drug-resistant pneumococcus. 2 In fact, the proportion of pneumococcal pathogens has declined significantly from 48% pre PCV-7 to 31% post PCV-7 (P =.007). We have also seen a moderate decrease in the rate of penicillin-nonsusceptible pneumococci from 25% to 19%; however, this decrease is not statistically significant. 2 Casey and Pichichero reported similar findings among children in Rochester, NY, with recurrent or persistent AOM (defined as nonresponders after 1 or 2 empiric antibiotic courses or failures after 48 hours on treatment) who had received PCV-7. 8 The authors found that 65% of recovered organisms during the period 2001 to 2003 were gram negative, 57% were H influenzae, and 55% were beta-lactamase positive H influenzae. So, I surmise that these microbiologic changes are probably occurring across the United States. 8 ASiM: What are the implications of the changing microbiology for future treatment of AOM as young children approach universal rates of PCV-7 vaccination with at least 3 doses? Dr Block: Once the vaccine supply is adequate, I believe we will continue to see a decline in the overall proportion of pneumococcal pathogens in AOM. We are now entering a gram-negative era for AOM. For coverage of both gram-negative pathogens and the residual penicillin-susceptible and intermediately resistant pneumococci, the third-generation cephalosporins and amoxicillin/clavulanate demonstrate excellent in vitro susceptibility and in vivo clinical efficacy in children with AOM. Amoxicillin/clavulanate has been accepted as the gold standard of treatment by the American Academy of Pediatrics/American Academy of Family Physicians (AAP/AAFP). 9 It is a very good drug for gram-negative pathogens as well as most strains of pneumococci. But with the emergence of H influenzae as the major pathogen in AOM and the increase in beta-lactamase producing organisms, certain thirdgeneration cephalosporins should be included in any armamentarium for the treatment of AOM as these agents also have excellent activity and cause less gastrointestinal disturbance. Among the third-generation oral cephalosporins, cefdinir, cefpodoxime, cefixime, and ceftibuten are available for the treatment of AOM. 10 Of the available third-generation cephalosporins, cefdinir and cefpodoxime have a distinct advantage in terms of both intermediate penicillin-nonsusceptible S pneumoniae and gram-negative coverage. 11,12 Cefixime provides limited pneumococcal coverage. 12 Ceftibuten does not provide coverage of pneumococcus or Moraxella catarrhalis, 13 and therefore should not be used in pediatric patients for AOM. Despite the coverage it provides, a real limitation of cefpodoxime oral suspension is that it receives low ratings for taste and aftertaste. 14 In contrast, cefdinir oral suspension receives high ratings for taste and aftertaste when compared with cefpodoxime or cefuroxime. 14 Both cefpodoxime and cefdinir can be administered once daily for 10 days or twice daily for 5 days. 10 These benefits of better taste and flexible dosing may help to improve patient adherence leading to better patient outcomes. Advanced Studies in Medicine S939
4 ASiM: How does the clinical efficacy of standarddose amoxicillin/clavulanate compare with that of the third-generation cephalosporins in the treatment of children with AOM? Dr Block: We conducted an investigator-blinded clinical trial comparing 5 days of cefdinir (14 mg/kg) given twice daily versus 10 days of amoxicillin/clavulanate (45 mg/kg of amoxicillin component) given twice daily. 15 We used low-dose amoxicillin/clavulanate in this study because the high-dose formulation was approved only 2 to 3 months before we began enrolling patients, and our study protocol had already undergone laborious revisions and approval by institutional review boards. This was a nontympanocentesis study that used clinical endpoints, and the diagnostic criteria for AOM were definitely adequate. In fact, our diagnostic criteria were more comprehensive than those in the AAP/AAFP guidelines because clinical signs/symptoms of otalgia, ear fullness, decreased hearing, or purulent discharge due to acute perforation of the tympanic membrane had to be associated with the presence in at least one ear of a minimum of 2 of the following: a bulging tympanic membrane, loss of the normal light reflex and tympanic membrane landmarks, and abnormal tympanic membrane mobility. Middle ear effusion was corroborated in all patients by acoustic reflectometry. 15 Based on data from experienced otoscopists using optimal culture technique for tympanocentesis, a pathogen should be present in 87% to 95% of cultures from an ear meeting these criteria In this particular study, the mean age of the children was 2.8 (±1.8) years, and 64% had received from 1 to 4 doses of PCV Overall, clinical response rates at the end-of-therapy visit (2-4 days post-therapy for either regimen) were equivalent between the 2 drugs (88% for cefdinir and 85% for amoxicillin/clavulanate). 15 However, among the subset of children who had ever received PCV-7, there was a statistically significant difference in efficacy favoring cefdinir over amoxicillin/clavulanate (92% vs 82%, P =.024; 95% confidence interval, 1.1 to 18.4). 15 When we looked specifically at children aged 6 to 24 months, in whom the occurrence of AOM is greatest, the impact of PCV-7 on drug efficacy was even more profound. Clinical cure rates were 92% for cefdinir compared with 77% for amoxicillin/clavulanate, with a P value of.019 when stratified by age. 15 The 95% confidence intervals were within 15% (3.5, 26.2), which is somewhat greater than the 10% that we would like to see. Our data indicate that cefdinir given twice a day for 5 days was very effective in children who had nonrefractory AOM, particularly among PCV-7 recipients. ASiM: Will high-dose amoxicillin remain an appropriate first-line therapy for AOM in children who are fully immunized with PCV-7? Dr Block: Although we may want to consider an antibiotic that provides better gram-negative coverage for initial therapy in children who have received PCV- 7, remember that our data and that from Casey and Pichichero were comprised mostly of children with recurrent or persistent AOM. 8 I believe high-dose amoxicillin should still remain first-line therapy for AOM. Amoxicillin is fairly inexpensive, extremely safe, modestly effective, and will cover a fair amount of pneumococcus and beta-lactamase negative strains of H influenzae. The use of this narrower-spectrum drug will help prevent the overuse of the more potent antibiotics in the all-too-often cases of diagnostic uncertainty, overdiagnosis, busy practitioners, and prescriptive pens susceptible to frequent parental pressure. Because the overall clinical efficacy of high-dose amoxicillin is reasonable and because infections with H influenzae and M catarrhalis may be less severe and often resolve without treatment, 19 at least initially with a tympanocentesis, high-dose amoxicillin is still an appropriate choice. ASiM: Will the changes in AOM microbiology in the PCV-7 era affect treatment choices for children who fail an initial course of therapy? Dr Block: When one looks at the sum total of the data, it looks like either amoxicillin/clavulanate or cefdinir should be the agent of choice when a child fails first-line therapy with amoxicillin. Both drugs have advantages and disadvantages. Amoxicillin/clavulanate probably has slightly better pneumococcal coverage, especially for penicillin-resistant pneumococcus. However, data from our practice and Casey s suggest that there has been a reduction in high-level resistance of pneumococci to penicillin since the introduction of PCV-7. 5 Among children 7 to 24 months of age, the choice between these agents is probably a flip of the coin. Cefdinir has some real advantages in terms of superior palatability and the fact that it can be administered once daily rather than twice daily for 10 days. These important benefits may help improve patient adher- S940 Vol. 4 (10E) December 2004
5 ence thereby improving the chances that a full course of therapy will be completed. Yet, for the clinician who sees patients daily, the AAP/AAFP guidelines indicate that amoxicillin/clavulanate is the only drug of choice for de novo AOM with fever or moderate to severe otalgia and for uncomplicated AOM that has failed to respond to initial antibiotic therapy. 9 But for the penicillin-allergic child or one who presents with vomiting, diarrhea, or an upset stomach, cefdinir would be the more appropriate choice. I believe it may be unwise to treat a child who has a fever and is not drinking or not eating well with amoxicillin/ clavulanate. If amoxicillin/clavulanate is not taken with substantial food or milk, it will commonly precipitate gastrointestinal distress. ASiM: Compared with standard-dose amoxicillin/clavulanate given twice daily for 10 days, would you expect adherence to be better with cefdinir given twice daily for 5 days and, if so, why? Dr Block: Yes, I would expect adherence to be better with the 5-day cefdinir regimen. Any time that duration of the dosing can be shortened, adherence can be improved. As for efficacy, I would recommend that for cefdinir, most clinicians should use a 10-day once-daily regimen for children younger than 2 years and for those who are treatment failures. Clinical trial experience with cefdinir and amoxicillin/clavulanate suggests that a standard 10-day course of therapy is preferable in younger children with AOM. 20,21 The 5- day twice-daily cefdinir regimen probably should be used only in children older than 2 years or in those with recurrent AOM who have not received antibiotics for at least a few weeks. ASiM: Could you comment on what some colleagues believe are limitations of this study; namely, the fact that you used standard-dose amoxicillin/clavulanate and did not do tympanocentesis? Dr Block: Those are the 2 biggest caveats to the data. With regard to the fact that we did not do tympanocentesis, some believe that clinical endpoints are not reliable as far as differentiating efficacy between drugs. However, there have been other clinical trials such as ours in which the evaluation of drug efficacy using clinical endpoints, rather than tympanocentesis plus cultures of middle ear fluid (MEF), clearly demonstrated between-treatment differences. This study showed a statistically significant difference between amoxicillin/clavulanate and cefdinir in children who had ever received PCV-7, with good P values and confidence intervals of 1.1 to As for the standard-dose of amoxicillin/clavulanate, children enrolled in the study were not otitis-prone and had not failed prior antibiotic therapy for AOM, the clinical setting in which high-dose amoxicillin/clavulanate should primarily be used at present. Another caveat to the data is that the mean age of 2.8 years for our patient population was a bit high. Ideally, in an AOM trial most of the children should be younger than 2 years because they are the hardest to treat and they tend to have the most failures. 22 ASiM: How would you differentiate some of the available cephalosporins? Dr Block: Let us compare cefdinir with cefprozil, both of which are commonly used cephalosporins. Cefprozil provides mainly gram-positive coverage, especially against pneumococcus, including penicillin intermediate-resistant strains. However, cefprozil provides minimal coverage for beta-lactamase negative or positive strains of H influenzae. The time above the MIC 90 (minimal inhibitory concentration) for this pathogen is only 21% of the dosage interval, 23 less than half that reported for cefpodoxime and, presumably, cefdinir. In addition, cefprozil has minimal activity against M catarrhalis; the MIC 90 is 8 mg/ml compared to that of 0.25 mg/ml for cefdinir. 13 Therefore, in the era of PCV-7 where two thirds of the pathogens are gram-negative, cefprozil probably does not have a major role and may not be better than placebo in terms of efficacy. Azithromycin, on the other hand, has some issues in terms of H influenzae coverage. Although azithromycin achieves concentrations in MEF that are consistently much higher than those in serum, it is believed by some to be tightly bound to the leckocytes. Two recent double tympanocentesis trials in children with uncomplicated AOM found that the standard azithromycin regimen (10 mg/kg on day 1, then 5 mg/kg on days 2 through 5) failed to eradicate H influenzae from MEF obtained on treatment days 3 to 6 in at least half of the patients (87% vs 39%, P =.0001). 24 The investigators suggest that the susceptibility breakpoints for H influenzae should be much lower Advanced Studies in Medicine S941
6 than at present for azithromycin. This would be consistent with the recent interpretation of Jacobs of susceptibility data for oral antibiotics using PK/PD (pharmacokinetic/pharmacodynamic) parameters. 25 Using these criteria, virtually all H influenzae isolates were susceptible to amoxicillin/clavulanate (98.3%), but only 5% were susceptible to cefaclor, azithromycin, or clarithromycin. 25 Thus, azithromycin may not be particularly effective for the treatment of AOM due to poor coverage of H influenzae at standard doses. ASiM: Do future trials need to consider the PCV-7 status of the children enrolled? Dr Block: I believe it is imperative that all future clinical trials of AOM address the PCV-7 status of the children enrolled in studies. As I alluded to earlier, the fourth or booster dose is probably much more important for protection against mucosal disease. Most penicillin-resistant pneumococcal strains are vaccine or vaccine-related serotypes. Our data suggest that the PCV-7 status of the study population may have a significant impact on the microbiologic and efficacy data obtained during the trial. Furthermore, it may not be valid to compare data from US children or those who have received PCV-7 with data from non-us children who have not received PCV-7. Except for Israel, non-us children usually have lower rates of infection due to H influenzae, particularly beta-lactamase positive strains. ASiM: Do you believe that future AOM treatment guidelines should consider the PCV-7 status of children, especially those aged 6 to 24 months? Dr Block: Definitely. At present amoxicillin/clavulanate is the only oral drug being recommended by the recent AAP/AAFP guidelines for AOM that fails to respond to initial antibiotic therapy. In the gram-negative era of PCV-7, thirdgeneration cephalosporins cefdinir and cefpodoxime, both of which have good coverage of H influenzae and most pneumococcus, should be included as routine second- or third-line choices along with amoxicillin/clavulanate. But in all fairness, when the current AAP/AAFP guidelines were developed, there were almost no data available on this microbial shift. Finally, because of its superior palatability and recent clinical trial data in PCV- 7 vaccinated children, cefdinir has an advantage over cefpodoxime liquid suspension. REFERENCES 1. Klein JO. Otitis media. Clin Infect Dis. 1994;19(5): Block SL, Hedrick J, Harrison CJ, et al. Community-wide vaccination with heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatr Infect Dis J. 2004;23(9): Black S, Shinefeld H, Pireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J. 2000;19(3): Fireman B, Black SB, Shinefeld HR, Lee J, Lewis E, Ray P. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J. 2003;22(1): Erratum in: Pediatr Infect Dis J. 2003;22(2): Black S, Shinefeld H, Baxter R, et al. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J. 2004;23(6): Block SL, Hedrick JA, Harrison CJ. Widespread use of conjugated pneumococcal vaccine significantly reduces rates of AOM and antibiotic usage. Presented at: the Society for Pediatric Research; May 2004; San Francisco, Calif. Abstract Block SL, Harrison CJ, Hedrick J, Tyler R, Smith A, Hedrick R. Restricted use of antibiotic prophylaxis for recurrent acute otitis media in the era of penicillin non-susceptible Streptococcus pneumoniae. Int J Pediatr Otorhinolaryngol. 2001;61(1): Casey JR, Pichichero ME. Changes in frequency and pathogens causing acute otitis media in Pediatr Infect Dis J. 2004;23(9): American Academy of Pediatrics/American Academy of Family Physicians Subcommittee on Management of Acute Otitis Media. Clinical practice guideline: Diagnosis and management of acute otitis media. Pediatrics. 2004;113(5): Physicians Desk Reference. 58th ed. Montvale, NJ: Thomson PDR; Sader HS, Fritsche TR, Mutnick AH, Jones RN. Contemporary evaluation of the in vitro activity and spectrum of cefdinir compared with other orally administered antimicrobials tested against common respiratory tract pathogens ( ). Diagn Microbiol Infect Dis. 2003;47(3): Pichichero ME. Acute otitis media: part II. Treatment in an era of increasing antibiotic resistance. Am Fam Physician. 2000;61(8): Dandekar PK, Nicolau DP. Pharmacodynamic considerations for the selection of oral cephalosporins in the treatment of rhinosinusitis. Otolaryngol Head Neck Surg. 2002;127(6, suppl):s10-s Steele RW, Thomas MP, Begue RE. Compliance issues related to the selection of antibiotic suspensions for children. Pediatr Infect Dis J. 2001;20(1): Block SL, Busman TA, Paris MM, Bukofzer S. Comparison of 5 day cefdinir treatment with 10-day low dose amoxicillin/clavulanate treatment for acute otitis media. Pediatr Infect Dis J. 2004;23(9): Block SL, Harrison CJ, Hedrick JA, et al. Penicillin-resistant Streptococcus pneumoniae in acute otitis media, risk factors, susceptibility patterns and antimicrobial management. Pediatr Infect Dis J. 1995;14(9): S942 Vol. 4 (10E) December 2004
7 17. Rodriguez WJ, Schwartz RH. Streptococcus pneumoniae causes otitis media with higher fever and more redness of tympanic membranes than Haemophilus influenzae or Moraxella catarrhalis. Pediatr Infect Dis. 1999;18(10): Del Beccaro MA, Mendelman PM, Inglis AF, et al. Bacteriology of acute otitis media: a new perspective. J Pediatr. 1992;120(1): Piglansky L, Leibovitz E, Raiz S, et al. Bacteriologic and clinical efficacy of high dose amoxicillin for therapy of acute otitis media in children. Pediatr Infect Dis J. 2003;22(5): Block SL, Kratzer J, Nemeth MA, Tack KJ. Five-day cefdinir course vs. ten-day cefprozil course for treatment of acute otitis media. Pediatr Infect Dis J. 2000;19(suppl 12):S147-S Hoberman A, Paradise JL, Burch DJ, et al. Equivalent efficacy and reduced occurrence of diarrhea from a new formulation of amoxicillin/clavulanate potassium (Augmentin) for treatment of acute otitis media in children. Pediatr Infect Dis J. 1997;16(5): Carlin SA, Marchant CD, Shurin PA, Johnson CE, Super DM, Rehmus JM. Host factors and early therapeutic response in acute otitis media. J Pediatr. 1991;118(2): Jacobs MR. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect. 2001;7(11): Dagan R, Johnson CE, McLinn S, et al. Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azitromycin in acute otitis media. Pediatr Infect Dis J. 2000;19(2): Jacobs MR. Building in efficacy: developing solutions to combat drug-resistant S pneumoniae. Clin Microbiol Infect. 2004;10(suppl 2): Advanced Studies in Medicine S943
Acute otitis media (AOM) is the most common bacterial
ORIGINAL STUDIES A Multicenter, Open Label, Double Tympanocentesis Study of High Dose Cefdinir in Children With Acute Otitis Media at High Risk of Persistent or Recurrent Infection Adriano Arguedas, MD,*
More informationComparative Efficacy and Safety Evaluation of Cefaclor VS Amoxycillin + Clavulanate in Children with Acute Otitis Media (AOM)
Special Article Comparative Efficacy and Safety Evaluation of Cefaclor VS Amoxycillin + Clavulanate in Children with Acute Otitis Media (AOM) Mukesh Aggarwal, Ramanuj Sinha 1, M. Vasudeva Murali 2, Prita
More informationChoosing an appropriate antimicrobial agent. 3) the spectrum of potential pathogens
Choosing an appropriate antimicrobial agent Consider: 1) the host 2) the site of infection 3) the spectrum of potential pathogens 4) the likelihood that these pathogens are resistant to antimicrobial agents
More informationSTUDY SELECTION AND DATA EXTRACTION:
Pediatrics Treatment and Prevention of Otitis Media John Erramouspe and Catherine A Heyneman OBJECTIVE: To review and summarize recent advances in the treatment and prevention of otitis media (OM). DATA
More informationEvelyn A. Kluka, MD FAAP November 30, 2011
Evelyn A. Kluka, MD FAAP November 30, 2011 > 80% of children will suffer from at least one episode of AOM by 3 years of age 40% will have > 6 recurrences by age 7 years Most common diagnosis for which
More informationHigh dose amoxicillin for sinusitis
High dose amoxicillin for sinusitis Amoxil ( amoxicillin ) is a commonly used penicillin antibiotic. It is produced in tablets (500 mg 875 mg), capsules, chewable tablets and oral suspensions. 6-3-2018
More informationThe Turkish Journal of Pediatrics 2007; 49:
The Turkish Journal of Pediatrics 2007; 49: 390-396 Original The comparison of single-dose ceftriaxone, five-day azithromycin, and ten-day amoxicillin/clavulanate for the treatment of children with acute
More informationReview Article Pneumococcal Conjugate Vaccines and Otitis Media: An Appraisal of the Clinical Trials
International Journal of Otolaryngology Volume 2012, Article ID 312935, 15 pages doi:10.1155/2012/312935 Review Article Pneumococcal Conjugate Vaccines and Otitis Media: An Appraisal of the Clinical Trials
More informationRecent guidelines for treating uncomplicated acute otitis
CASE-BASED REVIEW Using the 2004 AAP/AAFP Clinical Practice Guidelines on Diagnosis and Management of Acute Otitis Media Case Studies and Commentary, Christopher J. Harrison, MD The following article,
More informationAMERICAN ACADEMY OF PEDIATRICS AND AMERICAN ACADEMY OF FAMILY PHYSICIANS. Subcommittee on Management of Acute Otitis Media
AMERICAN ACADEMY OF PEDIATRICS AND AMERICAN ACADEMY OF FAMILY PHYSICIANS CLINICAL PRACTICE GUIDELINE Subcommittee on Management of Acute Otitis Media Diagnosis and Management of Acute Otitis Media ABSTRACT.
More informationPediatric Respiratory Infections
Pediatric Respiratory Infections Brenda Kelly PharmD BCPS Residency Program Director Virginia Mason Memorial, Yakima, Washington brendakelly@yvmh.org Disclosure The presenter has no actual or potential
More informationJimmy's Got Cooties! Common Childhood Infections and How Best to Treat Them
Jimmy's Got Cooties! Common Childhood Infections and How Best to Treat Them Objectives:! Recognize and manage several infections commonly seen in Pediatric practice! Discuss best practices and current
More informationAcute Otitis Media, Acute Bacterial Sinusitis, and Acute Bacterial Rhinosinusitis
Acute Otitis Media, Acute Bacterial Sinusitis, and Acute Bacterial Rhinosinusitis This guideline, developed by Larry Simmons, MD, in collaboration with the ANGELS team, on October 3, 2013, is a significantly
More informationUpdate on Rhinosinusitis 2013 AAP Guidelines Review
Update on Rhinosinusitis 2013 AAP Guidelines Review Carla M. Giannoni, MD Surgeon, Otolaryngology Texas Children's Hospital Professor, Surgery and Pediatrics, Baylor College of Medicine CDC: Acute Rhinosinusitis
More informationPediatric News. Management of Pediatric Pneumococcal Diseases in the Era of the Pneumococcal Conjugate Vaccine
A SUPPLEMENT TO Pediatric News Management of Pediatric Pneumococcal Diseases in the Era of the Pneumococcal Conjugate Vaccine Sponsored by Boston University School of Medicine Management of Acute Otitis
More informationUPPER RESPIRATORY TRACT INFECTIONS. IAP UG Teaching slides
UPPER RESPIRATORY TRACT INFECTIONS 1 INTRODUCTION Most common problem in children below 5 years. In this age group they get about 6 8 episodes per year. It includes infections of nasal cavity, throat,
More informationMulti-drug Resistant Serotype 19A Pneumococci in Toronto
TML Lab Rounds January 17, 2008 Multi-drug Resistant Serotype 19A Pneumococci in Toronto The Role of the Microbiology Lab Susan M. Poutanen, MD, MPH, FRCPC Microbiologist/ID Consultant, TML/MSH Assistant
More informationPneumococcal Vaccine Effectiveness. Steven Black, MD Center for Global Health Cincinnati Children s s Hospital Cincinnati, Ohio USA
Pneumococcal Vaccine Effectiveness Steven Black, MD Center for Global Health Cincinnati Children s s Hospital Cincinnati, Ohio USA Overview Possible effectiveness outcomes for pneumococcal vaccines Pre-licensure
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPneumococcal vaccines. Safety & Efficacy. Prof. Rajesh Kumar, MD PGIMER School of Public Health Chandigarh
Pneumococcal vaccines Safety & Efficacy Prof. Rajesh Kumar, MD PGIMER School of Public Health Chandigarh Disclosure Slide X X I DO NOT have any significant or other financial relationships with industry
More informationANTIBIOTICS ACUTE RHINOSINUSITIS IN CHILDREN
MARCH 2016 DRUG ANTIBIOTICS This optimal usage guide is mainly intended f primary care health professionnals. It is provided f infmation purposes only and should not replace the clinician s judgement.
More informationThe McMaster at night Pediatric Curriculum
The McMaster at night Pediatric Curriculum Community Acquired Pneumonia Based on CPS Practice Point Pneumonia in healthy Canadian children and youth and the British Thoracic Society Guidelines on CAP Objectives
More informationBenefits of the pneumococcal immunisation programme in children in the United Kingdom
Benefits of the pneumococcal immunisation programme in children in the United Kingdom 2006-2014 Professor Mary P E Slack mpeslack@gmail.com March 2015 Disclosure of interest The presenter has received
More informationPneumococcal infection is one of. Epidemiology of Pneumococcal Disease ...PRESENTATIONS... Based on a presentation by Chris Van Beneden, MD, MPH
...PRESENTATIONS... Epidemiology of Pneumococcal Disease Based on a presentation by Chris Van Beneden, MD, MPH Presentation Summary Pneumococcus is a leading cause of pneumonia and meningitis in the United
More informationPedsCases Podcast Scripts
PedsCases Podcast Scripts This is a text version of a podcast from Pedscases.com on Acute Otitis Media. These podcasts are designed to give medical students an overview of key topics in pediatrics. The
More informationManagement of URTI s in Children
Management of URTI s in Children Robin J Green PhD Antibiotics - Dilemmas for General Practitioners Antibiotic overuse = Resistance Delay in antibiotic use = Mortality Patient expectation Employer expectation
More informationAuthor's response to reviews
Author's response to reviews Title: Pneumococcal vaccination and otitis media in Australian Aboriginal infants: comparison of two birth cohorts before and after introduction of vaccination Authors: Grant
More informationPAEDIATRIC ACUTE CARE GUIDELINE. Otitis Media
Princess Margaret Hospital for Children PAEDIATRIC ACUTE CARE GUIDELINE Otitis Media Scope (Staff): Scope (Area): All Emergency Department Clinicians Emergency Department This document should be read in
More informationPopulation-based approaches: Regulatory issues and Population simulations
Population-based approaches: Regulatory issues and Population simulations Michael R. Jacobs, MD, PhD Case Western Reserve University University Hospitals of Cleveland Cleveland, OH Topics Regulatory issues
More informationType of intervention Treatment. Economic study type Cost-effectiveness analysis.
Nonsevere acute otitis media: a clinical trial comparing outcomes of watchful waiting versus immediate antibiotic treatment McCormick D P, Chonmaitree T, Pittman C, Saeed K, Friedman N R, Uchida T, Baldwin
More informationSINUSITIS. HAVAS ENT CLINICS Excellence in otolaryngology
JULY 2015 SINUSITIS WHAT IS IT? WHAT SHOULD YOU DO? WHAT WORKS? THOMAS E HAVAS MBBS (SYD) MD (UNSW) FRCSE, FRACS, FACS CONJOINT ASSOCIATE PROFESSOR UNSW OTOLARNGOLOGY HEAD AND NECK SURGERY HAVAS ENT CLINICS
More informationEconomic Impact of a Pneumococcal Conjugate Vaccine in Managed Care
...PRESENTATIONS... Economic Impact of a Pneumococcal Conjugate Vaccine in Managed Care Based on a presentation by Tracy Lieu, MD, MPH* Presentation Summary Conjugate pneumococcal vaccines may soon allow
More informationHigh-Dose Azithromycin versus High-Dose Amoxicillin-Clavulanate for Treatment of Children with Recurrent or Persistent Acute Otitis Media
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Oct. 2003, p. 3179 3186 Vol. 47, No. 10 0066-4804/03/$08.00 0 DOI: 10.1128/AAC.47.10.3179 3186.2003 Copyright 2003, American Society for Microbiology. All Rights
More information...REPORTS... Epidemiology of Pneumococcal Disease/ Rationale for and Efficacy of PnC7
...REPORTS... Epidemiology of Pneumococcal Disease/ Rationale for and Efficacy of PnC7 Summary A Streptococcus pneumoniae Conjugate Vaccine Managed Care Advisory Panel was presented with information on
More informationAcute otitis media microbiology in Costa Rican children
Etiology and Antimicrobial Susceptibility of Middle Ear Fluid Pathogens in Costa Rican Children With Otitis Media Before and After the Introduction of the 7-Valent Pneumococcal Conjugate Vaccine in the
More informationHaemophilus influenzae
Haemophilus influenzae type b Severe bacterial infection, particularly among infants During late 19th century believed to cause influenza Immunology and microbiology clarified in 1930s Haemophilus influenzae
More informationDELL CHILDREN S MEDICAL CENTER EVIDENCE-BASED OUTCOMES CENTER. Community Acquired Pneumonia
DELL CHILDREN S MEDICAL CENTER Community Acquired Pneumonia LEGAL DISCLAIMER: The information provided by Dell Children s Medical Center of Texas (DCMCT), including but not limited to Clinical Pathways
More informationPr Robert Cohen CHI Créteil France
EFFECT OF VACCINATION ON ANTIMICROBIAL RESISTANCE : THE EXAMPLE OF THE IMPACT OF PCVS ON ANTIBIOTIC RESISTANCE Pr Robert Cohen CHI Créteil France 1 DISCLOSURES I have received during the las 3 years honorarium
More informationDefinition. Otitis Media with effusion (OME)
Otitis Media. 1 Dr,wegdan saeed ALFHAL 2 Definition Acute Otitis Media (AOM) acute onset of symptoms, evidence of a middle ear effusion, and signs or symptoms of middle ear inflammation. Otitis Media with
More informationClinical Practice Guideline for the Diagnosis and Management of Acute Bacterial Sinusitis in Children Aged 1 to 18 Years
Organizational Principles to Guide and Define the Child Health Care System and/or Improve the Health of all Children CLINICAL PRACTICE GUIDELINE Clinical Practice Guideline for the Diagnosis and Management
More informationPotential Health and Economic Impact of new Pneumococcal Vaccines Against Acute Otitis Media in Canada
CPHA 2010 Potential Health and Economic Impact of new Pneumococcal Vaccines Against Acute Otitis Media in Canada Afisi S. Ismaila a,b, Jennifer A. Pereira c, Reid C. Robson a, Gerhart Knerer d a Medical
More informationImpact of different case definitions for acute otitis media on the efficacy estimates of a pneumococcal conjugate vaccine
Vaccine (2008) 26, 2466 2470 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/vaccine Impact of different case definitions for acute otitis media on the efficacy estimates of
More informationActivity of Faropenem against Middle Ear Fluid Pathogens from Children with Acute Otitis Media in Costa Rica and Israel
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, June 2007, p. 2230 2235 Vol. 51, No. 6 0066-4804/07/$08.00 0 doi:10.1128/aac.00049-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. Activity
More information2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
Measure #332: Adult Sinusitis: Appropriate Choice of Antibiotic: Amoxicillin With or Without Clavulanate Prescribed for Patients with Acute Bacterial Sinusitis (Appropriate Use) National Quality Strategy
More informationPrefe f rred d t e t rm: : rhi h no n s o inu n s u iti t s
HELP It s my sinuses! An overview of pharmacologic treatment of sinusitis Objectives Identify types of sinusitis and underlying pathology Examine common evidence based pharmacologic treatment for sinusitis
More informationPotential Impact of Conjugate Vaccine on the Incidence of Invasive Pneumococcal Disease among Children in Scotland
JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 2006, p. 1224 1228 Vol. 44, No. 4 0095-1137/06/$08.00 0 doi:10.1128/jcm.44.4.1224 1228.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved.
More informationCLINICAL PRACTICE. Clinical Practice. Diagnosis. Antibiotic Therapy. N Engl J Med, Vol. 347, No. 15 October 10, 2002
CLINICAL PRACTICE Clinical Practice This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review
More informationChanges Over Time in Nasopharyngeal Colonization in Children Under 2 Years of Age at the Time of Diagnosis of Acute Otitis Media ( )
Open Forum Infectious Diseases MAJOR ARTICLE Changes Over Time in Nasopharyngeal Colonization in Children Under 2 Years of Age at the Time of Diagnosis of Acute Otitis Media (1999 2014) Judith M. Martin,
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #332: Adult Sinusitis: Appropriate Choice of Antibiotic: Amoxicillin With or Without Clavulanate Prescribed for Patients with Acute Bacterial Sinusitis (Appropriate Use) National Quality Strategy
More informationVaccination and prophylaxis for asplenia: Guideline for clinicians
Vaccination and prophylaxis for asplenia: Guideline for clinicians Adults better health * better care * better value Acknowledgements The Western Australian Committee for Antimicrobials (WACA) would like
More informationThe Diagnosis and Management of Acute Otitis Media
Organizational Principles to Guide and Define the Child Health Care System and/or Improve the Health of all Children CLINICAL PRACTICE GUIDELINE The Diagnosis and Management of Acute Otitis Media abstract
More informationEvidence Based Practice Presentation
Evidence Based Practice Presentation Does the assessment of tympanic membrane mobility using pneumatic otoscopy reduce the diagnosis of Acute otitis media & otitis media with effusion in children? Ashley
More informationPharmacologyonline 1: (2010) ewsletter Singh and Kochbar. Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of
Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of Cefoperazone Sulbactam Singh M*, Kochhar P* Medical & Research Division, Pfizer India. Summary Antimicrobial resistance is associated with
More informationEconomic Evaluation of a Universal Childhood Pneumococcal Conjugate Vaccination Strategy in Ireland
Volume 11 Number 5 2008 VALUE IN HEALTH Economic Evaluation of a Universal Childhood Pneumococcal Conjugate Vaccination Strategy in Ireland Lesley Tilson, BSc (Pharm), PhD, 1 Cara Usher, BSc, PhD, 1 Karina
More informationDrug Class Review on Macrolides
Drug Class Review on Macrolides Preliminary Scan Report 5 July 2014 Last Report: Original August 2006 The purpose of reports is to make available information regarding the comparative clinical effectiveness
More informationJournal of Pediatric Sciences
Journal of Pediatric Sciences Buccal Cellulitis in 3 Infants Martin W Stallings Journal of Pediatric Sciences 2016;8:e252 http://dx.doi.org/10.17334/jps.78460 How to cite this article: Stallings MW. Buccal
More informationUpper Respiratory Tract Infections
Upper Respiratory Tract Infections OTITIS MEDIA Otitis media is an inflammation of the middle ear. There are more than 709 million cases of otitis media worldwide each year; half of these cases occur in
More informationGuidance for Industry Acute Bacterial Otitis Media: Developing Drugs for Treatment
Guidance for Industry Acute Bacterial Otitis Media: Developing Drugs for Treatment DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
More informationReceived 25 November 2002/Returned for modification 14 February 2003/Accepted 11 April 2003
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 2003, p. 2770 2774 Vol. 47, No. 9 0066-4804/03/$08.00 0 DOI: 10.1128/AAC.47.9.2770 2774.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationInternational Journal of Infectious Diseases
International Journal of Infectious Diseases 14 (2010) e197 e209 Contents lists available at ScienceDirect International Journal of Infectious Diseases journal homepage: www.elsevier.com/locate/ijid Review
More informationUpper Respiratory Tract Infections / 42
Upper Respiratory Tract Infections 1 Upper Respiratory Tract Infections Acute tonsillitispharyngitis Acute otitis media Acute sinusitis Common cold Acute laryngitis Otitis externa Mastoiditis Acute apiglottis
More informationStreptococcus pneumoniae
Streptococcus pneumoniae EPIDEMIOLOGY AND PREVENTION 2^4. November 2007 Prof. Dr. Kathrin Mühlemann Klinik und Poliklinik für Infektionskrankheiten Universität Bern, INSELSPITAL S. pneumoniae: epidemiology
More informationOtitis media: a review for the Family physician
Otitis media: a review for the Family physician Rehab Alwotayan 1, Khaled Alabdulhadi 1 Otitis media (OM) is a serious healthcare concern worldwide. Acute otitis media is over-diagnosed. Symptoms are neither
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Hoberman A, Paradise JL, Rockette HE, et al. Shortened antimicrobial
More informationIncidence per 100,000
Streptococcus pneumoniae Surveillance Report 2005 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Department of Human Services Updated: March 2007 Background
More informationBCG vaccine and tuberculosis
PART 2: Vaccination for special risk groups 2.1 Vaccination for Aboriginal and Torres Strait Islander people Aboriginal and Torres Strait Islander people historically had a very high burden of infectious
More informationORIGINAL ARTICLE. Pneumococcal acute otitis media in children
ORIGINAL ARTICLE Pneumococcal acute otitis media in children G. Kouppari 1, A. Zaphiropoulou 1, G. Stamos 1, V. Deliyianni 1, N. Apostolopoulos 2 and N. J. Legakis 3 1 Microbiology Laboratory, 2 ENT Department
More informationAssociation of Clinical Signs and Symptoms with Pneumococcal Acute Otitis Media by Serotype Implications for Vaccine Effect
MAJOR ARTICLE Association of Clinical Signs and Symptoms with Pneumococcal Acute Otitis Media by Serotype Implications for Vaccine Effect Arto A. I. Palmu, 1,2 Jukka T. Jokinen, 1 Tarja Kaijalainen, 1
More informationEPIREVIEW INVASIVE PNEUMOCOCCAL DISEASE, NSW, 2002
EPIREVIEW INVASIVE PNEUMOCOCCAL DISEASE, NSW, 2002 Robyn Gilmour Communicable Diseases Branch NSW Department of Health BACKGROUND Infection with the bacterium Streptococcus pneumoniae is a major cause
More informationACCURATE DETERMINATION
ARTICLE Spectral Gradient Acoustic Reflectometry Compared With Tympanometry in Diagnosing Middle Ear Effusion in Children Aged 6 to 24 Months Jennifer Chianese, MD; Alejandro Hoberman, MD; Jack L. Paradise,
More informationRespiratory tract infections. Krzysztof Buczkowski
Respiratory tract infections Krzysztof Buczkowski Etiology Viruses Rhinoviruses Adenoviruses Coronaviruses Influenza and Parainfluenza Viruses Respiratory Syncitial Viruses Enteroviruses Etiology Bacteria
More informationUSAID Health Care Improvement Project. pneumonia) respiratory infections through improved case management (amb/hosp)
Improvement objective: : decrease morbidity and mortality due to acute upper (rhinitis, sinusitis, pharyngitis) and lower (bronchitis, pneumonia) respiratory infections through improved case management
More informationAXITAB-CV TAB. COMPOSITION :
AXITAB-CV TAB. COMPOSITION : Each film coated tablet contains: Cefuroxime Axetil I.P. Eq. to Anhydrous 500mg. Potassium Clavulanate Diluted I.P. Eq. to Clavulanic Acid 125mg DESCRIPTION : Cefuroxime Axetil
More informationImpact of Universal Infant Immunization with Pneumococcal (Streptococcus pneumonia) Conjugate Vaccines in Alaska
Pacific University CommonKnowledge School of Physician Assistant Studies Theses, Dissertations and Capstone Projects 8-2008 Impact of Universal Infant Immunization with Pneumococcal (Streptococcus pneumonia)
More informationI have no disclosures
Disclosures Streptococcal Pharyngitis: Update and Current Guidelines Richard A. Jacobs, MD, PhD Emeritus Professor of Medicine Division of Infectious Diseases I have no disclosures CID 2012:55;e 86-102
More informationAcute Otitis Media and Acute Bacterial Sinusitis
SUPPLEMENT ARTICLE Acute Otitis Media and Acute Bacterial Sinusitis Ellen R. Wald Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin Acute otitis
More informationRisk profiles and vaccine uptake in children with invasive pneumococcal disease at a tertiary hospital in Tshwane:
Risk profiles and vaccine uptake in children with invasive pneumococcal disease at a tertiary hospital in Tshwane: A retrospective review Xandré Dearden www.up.ac.za IPD: disease spectrum and epidemiology
More informationFacilitator s Guide. Prescription Writing/Patient Safety Author: Benjamin Estrada, MD, University of South Alabama. Active Learning Module
Facilitator s Guide Prescription Writing/Patient Safety Author: Benjamin Estrada, MD, University of South Alabama Active Learning Module Core Concepts In order to master this topic area, students must
More informationTo develop guidelines for the use of appropriate antibiotics for adult patients with CAP and guidance on IV to PO conversion.
Page 1 of 5 TITLE: COMMUNITY-ACQUIRED PNEUMONIA (CAP) EMPIRIC MANAGEMENT OF ADULT PATIENTS AND IV TO PO CONVERSION GUIDELINES: These guidelines serve to aid clinicians in the diagnostic work-up, assessment
More informationAcute Bacterial Sinusitis: The latest treatment recommendations. Objectives Having completed the learning activities, the participant will be able to:
Acute Bacterial Sinusitis: The latest treatment recommendations Presented by: Monica Tombasco, MS, MSNA, FNP-BC, CRNA Senior Lecturer Fitzgerald Health Education Associates, Inc., North Andover, MA Emergency
More information4/11/2017 COMMUNITY ACQUIRED PNEUMONIA. Disclaimer. A Review of How to Treat Common Infections in a Pediatric Patient. Objectives for Technicians
Disclaimer A Review of How to Treat Common Infections in a Pediatric Patient Tara Bergland reports that she has no actual or potential conflict of interest in relation to this presentation. Off label use
More informationMolina Healthcare of Washington, Inc. Guideline for the Judicious use of Antibiotics
Molina Healthcare of Washington, Inc. Guideline for the Judicious use of Antibiotics The Washington State Clinical Practice Guidelines for the Judicious Use of Antibiotics in URI (Sinusitis, Otitis Media,
More informationSYNOPSIS. The study results and synopsis are supplied for informational purposes only.
SYNOPSIS INN : LEVOFLOXACIN Study number : LOFBO-OTMD-002 Study title : A Multicenter, Randomized, Comparative Study to Evaluate the Efficacy and Safety of Levofloxacin in the Treatment of Children Who
More informationAnnual Epidemiological Report
August 2018 Annual Epidemiological Report Key Facts Streptococcus 1Pneumoniae (invasive) in Ireland, 2017 In 2017, 415 confirmed cases of invasive pneumococcal diseases (IPD) were reported in Ireland,
More informationCommunity Acquired Pneumonia - Pediatric Clinical Practice Guideline MedStar Health Antibiotic Stewardship
Community Acquired Pneumonia - Pediatric Clinical Practice Guideline MedStar Health Antibiotic Stewardship These guidelines are provided to assist physicians and other clinicians in making decisions regarding
More informationThe Bacteriology of Bronchiectasis in Australian Indigenous children
The Bacteriology of Bronchiectasis in Australian Indigenous children Kim Hare, Amanda Leach, Peter Morris, Heidi Smith-Vaughan, Anne Chang Presentation outline What is bronchiectasis? Our research at Menzies
More informationAn Open Multicenter Study of the Use of Gatifloxacin for the Treatment of Non- Complicated Acute Bacterial Rhinosinusitis in Adults
162 BJID 2005; 9 (April) An Open Multicenter Study of the Use of Gatifloxacin for the Treatment of Non- Complicated Acute Bacterial Rhinosinusitis in Adults Weckx L.L.M. 1, Campos C.A.H. 2, Sakano E. 3,
More informationKAISER PERMANENTE OHIO COMMUNITY ACQUIRED PNEUMONIA
KAISER PERMANENTE OHIO COMMUNITY ACQUIRED PNEUMONIA Methodology: Expert opinion Issue Date: 8-97 Champion: Pulmonary Medicine Most Recent Update: 6-08, 7-10, 7-12 Key Stakeholders: Pulmonary Medicine,
More informationUpper Respiratory tract Infec1on. Gassem Gohal FAAP FRCPC
Upper Respiratory tract Infec1on Gassem Gohal FAAP FRCPC Anatomy Contents Sinusitis Common Cold Otitis media pharyngitis Epiglottitis Croup Trachitis Sinuses Sinus development Born with ME ( Maxillary,
More informationOtitis Media: The Answer
Volume 2, Number 5 Otitis Media: The Answer Table of Contents Technical Requirements 2 Learning Objectives 2 CME Requirements 2 Session Transcript 3 References 13 Test Questions 14 Evaluation 15 Kurt Metzl,
More informationFive New Clinical Guidelines in Primary Care: What we all need to know. Learning Objectives. Clinical Practice Guidelines
Five New Clinical Guidelines in Primary Care: What we all need to know Annie Abraham, MSN, RN, FNP-BC Assistant Clinical Professor Texas Woman s University Dallas, TX Learning Objectives Discuss up-to-date
More informationRecommended Childhood Immunization Schedu...ates, January - December 2000, NP Central
Recommended Childhood Immunization Schedule United States, January - December 2000 Vaccines 1 are listed under routinely recommended ages. Solid-colored bars indicate range of recommended ages for immunization.
More informationStreptococcus Pneumoniae
Streptococcus Pneumoniae (Invasive Pneumococcal Disease) DISEASE REPORTABLE WITHIN 24 HOURS OF DIAGNOSIS Per N.J.A.C. 8:57, healthcare providers and administrators shall report by mail or by electronic
More informationACIP Recommendations for Pneumococcal 13-valent Conjugate and 23-valent Polysaccharide Vaccine Use among Adults
ACIP Recommendations for Pneumococcal 13-valent Conjugate and 23-valent Polysaccharide Vaccine Use among Adults National Center for Immunization & Respiratory Diseases Respiratory Diseases Branch ACIP
More informationRunning head: OTITIS MEDIA AUGMENTIN VERSUS WATCHFUL WAITING 1
Running head: OTITIS MEDIA AUGMENTIN VERSUS WATCHFUL WAITING 1 Evidence Based Critically Appraised Topic Otitis Media and using Augmentin versus watchful waiting Ann Sarutzki-Tucker University of Mary
More informationAlabama Medicaid Pharmacist
Published Quarterly by Health Information Designs, LLC, Summer 2013 edition A Service of Alabama Medicaid PDL Update Effective July 1, 2013, the Alabama Medicaid Agency will update the Preferred Drug List
More informationAppendix A: Disease-Specific Chapters
Ministry of Health and Long-Term Care Infectious Diseases Protocol Appendix A: Disease-Specific Chapters Chapter: Haemophilus influenzae disease, all types, invasive Effective: May 2018 Haemophilus influenzae,
More information